These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8804744)

  • 1. Fostering partnerships for vaccine development: a delicate fabric.
    Douglas RG
    Bull N Y Acad Med; 1996; 73(1):113-23. PubMed ID: 8804744
    [No Abstract]   [Full Text] [Related]  

  • 2. The benefits and threats of research partnerships with industry.
    Duval G
    Crit Care; 2005 Aug; 9(4):309-10. PubMed ID: 16137365
    [No Abstract]   [Full Text] [Related]  

  • 3. Maintaining the vaccine safety net.
    Hannan C; Buchanan AD; Monroe J
    Pediatrics; 2009 Dec; 124 Suppl 5():S571-2. PubMed ID: 19948593
    [No Abstract]   [Full Text] [Related]  

  • 4. Industry, governments, and nonprofits worldwide join effort to develop AIDS vaccine.
    AIDS Patient Care STDS; 1996 Oct; 10(5):310-1. PubMed ID: 11361530
    [No Abstract]   [Full Text] [Related]  

  • 5. A work in progress.
    Bloice C; Hallinan C
    Revolution (Oakl); 2005; 6(6):14-21. PubMed ID: 16422557
    [No Abstract]   [Full Text] [Related]  

  • 6. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine partnerships to tackle neglected diseases.
    Hughes B
    Nat Rev Drug Discov; 2008 Apr; 7(4):277-8. PubMed ID: 18396477
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 9. United States vaccine research: a delicate fabric of public and private collaboration.
    Marcuse EK
    Pediatrics; 1998 Oct; 102(4 Pt 1):1002-3. PubMed ID: 9786767
    [No Abstract]   [Full Text] [Related]  

  • 10. The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration.
    Vitiello B; Heiligenstein JH; Riddle MA; Greenhill LL; Fegert JM
    Biol Psychiatry; 2004 Jul; 56(1):3-9. PubMed ID: 15219466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical sciences in 2020.
    Crommelin D; Stolk P; Besançon L; Shah V; Midha K; Leufkens H
    Nat Rev Drug Discov; 2010 Feb; 9(2):99-100. PubMed ID: 20118959
    [No Abstract]   [Full Text] [Related]  

  • 12. New technology, old struggles plague vaccine developers.
    Phillips L
    Hosp Technol Ser; 1994 Oct; 13(13):3-6. PubMed ID: 10137963
    [No Abstract]   [Full Text] [Related]  

  • 13. Public health. U.S. vaccine supply falls seriously short.
    Cohen J
    Science; 2002 Mar; 295(5562):1998-2001. PubMed ID: 11896251
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of US government agencies in vaccine research and development.
    Folkers GK; Fauci AS
    Nat Med; 1998 May; 4(5 Suppl):491-4. PubMed ID: 9585193
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative effectiveness casts first shadows across US industry.
    Waltz E
    Nat Biotechnol; 2009 Mar; 27(3):211-2. PubMed ID: 19270651
    [No Abstract]   [Full Text] [Related]  

  • 16. Vaccine renaissance.
    Almond JW
    Nat Rev Microbiol; 2007 Jul; 5(7):478-81. PubMed ID: 17571456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine and microbicide tax credit legislation introduced in Congress.
    AIDS Treat News; 1999 Apr; (No 316):7-8. PubMed ID: 11366301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperative agreement for Applied Research on Surveillance of Vaccine Preventable Diseases in Managed Care Settings; notice of availability of funds. Centers for Disease Control and Prevention.
    Fed Regist; 1999 May; 64(93):26419-21. PubMed ID: 10558533
    [No Abstract]   [Full Text] [Related]  

  • 19. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

  • 20. The winning shot. New vaccine technologies to offer pinpoint attacks on a variety of potentially deadly diseases.
    Kirchheimer B
    Mod Healthc; 2005 Nov; 35(46):52-4. PubMed ID: 16334833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.